EUVIMEDEUVIMED entdecken
Open Access

Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation

Mousa Kharnaf, Farhan Zafar, Spencer Hogue, Leah Rosenfeldt, Rachel L Cantrell, Bal Krishan Sharma, Amelia Pearson, Cassandra Sprague, Daniel Leino, William A Abplanalp, Wioleta M Zelek, Keith R McCrae und 5 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2024

DOI: 10.1016/j.jtcvs.2023.08.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024. Verfasst von Mousa Kharnaf und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic…. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Factor XII, Thrombosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Factor XII (FXII) is a multifunctional protease capable of activating thrombotic and inflammatory pathways. FXII has been linked to thrombosis in extracorporeal membrane oxygenation (ECMO), but the role of FXII in ECMO-induced inflammatory complications has not been studied. We used novel gene-targeted FXII- deficient rats to evaluate the role of FXII in ECMO-induced thromboinflammation. METHODS: FXII-deficient (FXII-/-) Sprague-Dawley rats were generated using CRISPR/Cas9. A minimally invasive venoarterial (VA) ECMO model was used to compare wild-type (WT) and FXII-/- rats in 2 separate experimental cohorts: rats placed on ECMO without pharmacologic anticoagulation and rats anticoagulated with argatroban. Rats were maintained on ECMO for 1 hour or until circuit failure occurred. Comparisons were made with unchallenged rats and rats that underwent a sham surgical procedure without ECMO. RESULTS: FXII-/- rats were maintained on ECMO without pharmacologic anticoagulation with low resistance throughout the 1-hour experiment. In contrast, WT rats placed on ECMO without anticoagulation developed thrombotic circuit failure within 10 minutes. Argatroban provided a means to maintain WT and FXII-/- rats on ECMO for the 1-hour time frame without thrombotic complications. Analyses of these rats demonstrated that ECMO resulted in increased neutrophil migration into the liver that was significantly blunted by FXII deficiency. ECMO also resulted in increases in high molecular weight kininogen cleavage and complement activation that were abrogated by genetic deletion of FXII. CONCLUSIONS: FXII initiates hemostatic system activation and key inflammatory sequelae in ECMO, suggesting that therapies targeting FXII could limit both thromboembolism and inopportune inflammatory complications in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracorporeal Membrane OxygenationFactor XIIThrombosisAnimalsMaleRatsAnticoagulantsArginineBlood CoagulationDisease Models, AnimalFactor XII DeficiencyInflammationPipecolic AcidsRats, Sprague-DawleySulfonamides

Stichwörter der Autor:innen

complementextracorporeal circulationfactor XIIhigh molecular weight cleavageinflammationneutrophil

Substanzen

AnticoagulantsargatrobanArginineFactor XIIPipecolic AcidsSulfonamides

Autor:innen und Institutionen

  • The Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: moosakernaf@gmail.com.
  • The Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Department of Pathology, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Systems Immunity Research Institute and Dementia Research Institute, Cardiff University, Cardiff, United Kingdom.
  • Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio.

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Kharnaf, M., Zafar, F., Hogue, S., Rosenfeldt, L., Cantrell, R. L., Sharma, B. K., Pearson, A., Sprague, C., Leino, D., Abplanalp, W. A., Zelek, W. M., McCrae, K. R., Shim, Y. J., Morales, D., Tweddell, J., Qualls, J. E., & Palumbo, J. S. (2024). Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2023.08.045

Vancouver

Kharnaf M, Zafar F, Hogue S, Rosenfeldt L, Cantrell RL, Sharma BK, et al. Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation. The Journal of Thoracic and Cardiovascular Surgery. 2024. doi:10.1016/j.jtcvs.2023.08.045

BibTeX
@article{Kharnaf2024,
  author = {Kharnaf, Mousa and Zafar, Farhan and Hogue, Spencer and Rosenfeldt, Leah and Cantrell, Rachel L and Sharma, Bal Krishan and Pearson, Amelia and Sprague, Cassandra and Leino, Daniel and Abplanalp, William A and Zelek, Wioleta M and McCrae, Keith R and Shim, Young Jun and Morales, David and Tweddell, James and Qualls, Joseph E and Palumbo, Joseph S},
  title = {Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2024},
  doi = {10.1016/j.jtcvs.2023.08.045}
}
Kostenlos starten →